# National Cancer Institute

MATERIAL TRANSFER AGREEMENT-A

# Cell lines maintained in the NCI-DCTD Repository

This Material Transfer Agreement ("MTA") has been adopted for use by the National Cancer Institute ("NCI") for transfers of cell lines from the Division of Cancer Treatment and Diagnosis ("DCTD") Tumor Repository. Since the early 1960's, the DCTD Tumor Repository has maintained a low temperature repository of transplantable tumor and tumor cell lines from various species. The Repository serves as a resource for experimental tumor lines from various species, many of which are not obtainable elsewhere. The Repository makes these materials, other than patient-derived xenograft (PDX) cancer models, available as a service to the research community.

Recipient Institution: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (“Recipient”)

Recipient Investigator: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. NCI agrees to transfer to Recipient named above the following material from the DCTD Tumor Repository (“Research Material”):

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 The Research Material is provided in a manner that does not allow for direct identifiable patient information to the Recipient, and therefore does not constitute Human Subject Research as defined in 45 CFR Part 46, “Protection of Human Subjects”.

1. **The Research Material may not be used in human subjects or for the treatment or diagnosis of disease.** The Research Material will only be used for research purposes by Recipient's investigator in his/her laboratory, for the research project described below, under suitable containment conditions. This Research Material will not be used for commercial purposes such as production or sale of the Research Material or sales of services using the Research Material. Recipient agrees to use the Research Material in compliance with all applicable laws and regulations.
2. This Research Material will be used by Recipient's investigator solely in connection with the following research project ("Research Project") described with specificity as follows (use an attachment page if necessary):

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. The Recipient agrees to acknowledge NCI's contribution of this Research Material in any oral presentations or written publications reporting use of the Research Material unless requested otherwise by NCI.
2. To the extent permitted by law, Recipient agrees to treat in confidence, for a period of three (3) years from the date of its disclosure, any of NCI's written information about this Research Material that is stamped **"CONFIDENTIAL,"** except for information that was previously known to Recipient or that is or becomes publicly available or which is disclosed to Recipient without a confidentiality obligation or is required to be disclosed by law. Any oral disclosures from NCI to Recipient shall be identified as being **CONFIDENTIAL** by notice delivered to Recipient within ten (10) days after the date of the oral disclosure. Recipient may publish or otherwise publicly disclose the results of the Research Project, but if NCI has given **CONFIDENTIAL** information to Recipient such public disclosure may be made only after NCI has had thirty (30) days to review the proposed disclosure to determine if it includes any **CONFIDENTIAL** information, except when a shortened time period under court order or the Freedom of Information Act pertains.
3. This Research Material represents a significant investment on the part of NCI. Recipient's investigator therefore agrees to retain control over this Research Material and further agrees not to transfer the Research Material to other people not under her or his direct supervision without advance written approval of NCI. NCI reserves the right to distribute the Research Material to others and to use it for its own purposes. When the Research Project is completed or five (5) years have elapsed, whichever occurs first, the Research Material will be destroyed, unless otherwise directed by NCI, and the Recipient will provide written certification of the destruction to NCI within two (2) weeks of destruction. Recipient may continue to use the Research Materials beyond five (5) years upon execution of a new MTA.
4. The Research Material delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. **The NCI makes no representations and extends no warranties of any kind, either expressed or implied. There are no express or implied warranties of merchantability or fitness for a particular purpose, or that the use of the Research Material will not infringe any patent, copyright, trademark, or other proprietary rights of third parties.** Unless prohibited by law, Recipient assumes all liability for claims for damages against it by third parties which may arise from the use, storage or disposal of the Research Material by the Recipient except that, to the extent permitted by law, the NCI will be liable to the Recipient when the damage is caused by the gross negligence or willful misconduct of the NCI.
5. Recipient may retain title to the patent rights in inventions made by its employees in the course of the Research Project. Recipient agrees not to claim, infer, or imply Governmental endorsement of the Research Project, the institution or personnel conducting the Research Project or any resulting product(s).
6. The undersigned Recipient expressly certifies and affirms that the contents of any statements made herein are truthful and accurate.

**SIGNATURE PAGE**

**RECIPIENT**

Agreed by:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_

**Authorized Signature and Title, for Recipient’s Institution** Date

**(Note- Authorized Signature has the authority to bind the Institution to the terms of this agreement.)**

Recipient's Shipping Address:

Email:

Phone:Billing Info (if different; for shipping and handling):

Acknowledged by:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_

**Recipient** **Investigator’s Signature and Title Date**

Phone:\_\_\_\_\_\_\_\_\_\_\_ Fax:\_\_\_\_\_\_\_\_\_\_\_\_\_ Email:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**NCI**

Agreed by:

Authorized Signature for NCI: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

 **Melinda G. Hollingshead, D.V.M., Ph.D., Chief, BTB, DTP, DCTD, NCI, NIH**

NCI's Mailing Address:

BTB/DTP/DCTD/NCI/NIH

Frederick, MD USA 21702

Email: DCTDTumorRepository@mail.nih.gov